Superworth

Alnylam Pharmaceuticals price to book ratio ALNY

Market value divided by the book value of the company's net assets, since 2010.

Today, Nov 3, 2026
15.7×
10-year median
10.9×
Against its 10-year history
63rd
percentile: 0 is its lowest day, 100 its highest
10-year range
2.9× to 191×
Peer median
5.0×

Alnylam Pharmaceuticals' price to book ratio is 15.7× as of Nov 3, 2026.

That is above its ten-year median of 10.9×, close to the middle of its last ten years.

Over that time it ranged from 2.9× in Nov 2016 to 191× in Jan 2026.

The median for 10 biotech stocks of a similar size is 5.0×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far15.6×15.6×191×
2025n/m a value too high to mean anything
2024n/m a value too high to mean anything
2023n/m a value too high to mean anything
2022136×20.9×159×
202126.8×14.0×30.8×
202012.4×7.9×13.8×
20198.2×4.6×8.6×
20184.8×4.3×11.8×
201711.1×3.2×12.3×
20163.2×2.7×6.1×
20156.0×4.8×10.6×
20148.3×4.2×21.4×
201313.9×5.1×14.2×
20125.2×2.6×5.8×
20112.7×2.0×3.0×
20102.6×2.4×3.8×

Against its peers

Companies in Biotechnology nearest Alnylam Pharmaceuticals' size, closest first, today.

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Alnylam Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.